Advertisement

European Journal of Epidemiology

, Volume 33, Issue 3, pp 259–261 | Cite as

Human papillomavirus vaccine: Urgent need to promote gender parity

  • Cédric Abat
  • Didier Raoult
COMMENTARY
In this issue of the Journal, Shield et al. [ 1] outline the leading role of human papillomavirus (HPV) in human cancers by identifying it as the leading infectious cause of cancers in France in 2015 with 6333 of the 352,000 new cancer cases identified over this year at the national level attributable to HPV [4580 new cancers in women (72.3% of the total) and 1753 new cancer cases in males (27.7% of the total)]. They reported that the three most prevalent HPV-attributable cancers in France were cervical cancers (2917 new cancer cases) followed by anal cancers (1458 new cancer cases) and oropharyngeal cancers (1371 new cancer cases) (Table  1) [ 1].
Table 1

Worldwide (2012), Europe (2012) and national (2015) estimates of the number of new cancer cases attributable to Human papillomavirus (HPV)

HPV-related cancer site

Worlda

Europea,b

Francec

All

Males

Females

All

Males

Females

All

Males

Females

Cervical cancers

530,000

0

530,000

58,000

0

58,000

2917

0

2917

Anal cancers

35,000

17,000

18,000

References

  1. 1.
    Shield KD, Marant Micallef C, de Martel C, Heard I, Megraud F, Plummer M, et al. New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis. Eur J Epidemiol. 2018.  https://doi.org/10.1007/s10654-017-0334-z.Google Scholar
  2. 2.
    Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Prim. 2016;2:16086.CrossRefPubMedGoogle Scholar
  3. 3.
    de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2017;47:2–13.CrossRefPubMedGoogle Scholar
  4. 4.
    HCSP. Vaccination des garçons contre les infections à papillomavirus. 2016. http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspr20160219_recovaccinfhpvhommes.pdf.
  5. 5.
    Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–16.CrossRefPubMedGoogle Scholar
  6. 6.
    de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–70.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pincock S. Virologist wins Nobel for cervical cancer discovery. Lancet. 2008;372:1374.CrossRefPubMedGoogle Scholar
  8. 8.
    Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136:2752–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2017;47:42–58.CrossRefPubMedGoogle Scholar
  10. 10.
    Michels KB, zur Hausen H. HPV vaccine for all. Lancet. 2009;374:268–70.CrossRefPubMedGoogle Scholar
  11. 11.
    Uhart M, Adam M, Dahlab A, Bresse X. Loss of chance associated with sub-optimal HPV vaccination coverage rate in France. Papillomavirus Res. 2017;3:73–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Fonteneau L, Ragot M, Parent du Châtelet I, Guthmann J-P, Lévy-Bruhl D. The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety. BMC Public Health. 2015;15:1233.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    HCSP. Avis relatif à la révision de l’âge de vaccination contre les infections à papillomavirus humains des jeunes filles. 2012. http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20120928_agevaccpapilljeunesfilles.pdf.
  14. 14.
    HCSP. Vaccinations des personnes immunodéprimées ou aspléniques_Recommandations. 2012. http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspr20120712_vaccinationimmunodeprime.pdf.
  15. 15.
    Ventimiglia E, Horenblas S, Muneer A, Salonia A. Human papillomavirus infection and vaccination in males. Eur Urol Focus. 2016;2:355–62.CrossRefPubMedGoogle Scholar
  16. 16.
  17. 17.
    Fonteneau L, Guthmann J-P, Lévy-Bruhl D. Estimation des couvertures vaccinales en France à partir de l’Échantillon généraliste des bénéficiaires (EGB): exemples de la rougeole, de l’hépatite B et de la vaccination HPV. Bull Epidemiol Hebd. 2013;7:72–6.Google Scholar
  18. 18.
    Brotherton JM, Winch KL, Bicknell L, Chappell G, Saville M. HPV vaccine coverage is increasing in Australia. Med J Aust. 2017;206:262.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.IRD, MEPHI, AP-HM, IHU-Méditerranée-InfectionAix-Marseille UniversityMarseilleFrance

Personalised recommendations